Additionally, the detection of a TP53 variant at lower VAFs (10–40%) in blood DNA (suggesting germline mosaicism) should be confirmed with supplementary tests that assess the presence of the TP53 variant in unaffected tissues with no lymphocyte content (e.g., skin biopsy, follicle bulbs), to rule out other possibilities, such as TP53 clonal hematopoiesis of indeterminate potential (CHIP) or circulating tumor DNA [16–18] (Fig. 1). Here, TP53 is linked to neoplasm.